Guselkumab for the Treatment of Psoriasis: A Review of Phase III Trials

INTRODUCTION: Interleukin (IL)-23 inhibitors are a new class of biologics currently undergoing clinical trials for the treatment of moderate-to-severe psoriasis. Phase III studies of guselkumab, an IL-23 receptor monoclonal antibody, are currently underway. METHODS: We summarize the available phase...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Dermatol Ther (Heidelb)
Asıl Yazarlar: Nakamura, Mio, Lee, Katherine, Jeon, Caleb, Sekhon, Sahil, Afifi, Ladan, Yan, Di, Lee, Kristina, Bhutani, Tina
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Springer Healthcare 2017
Konular:
Review
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5574739/
https://ncbi.nlm.nih.gov/pubmed/28639011
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13555-017-0187-0
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller